Publications

Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase 1 clinical trial

Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression…

[177Lu]Lu-DPI-4452 & [68Ga]Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models

Antimicrobial activity of the new FabI inhibitor Afabicin desphosphono against intraosteoblastic Staphylococcus aureus

First-in-Human phase 1 study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced…

Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid

Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123

Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota